Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017

Diabetes & Metabolism Journal

¹  Sang Youl Rhee²  Seok-O Park³  Min Kyong Moon⁴  Jin Hwa Kim⁵  Hyun Jin Kim⁶  Seung-Hyun Ko⁷  Kyung Mook Choi⁸  Nan-Hee Kim⁸  Kyu-Yeon Hur⁹  Byung-Wan Lee^1,10 

[1] ;Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.;Department of Internal Medicine, Gwangmyeong Sungae Hospital, Gwangmyeong, Korea.;Department of Internal Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.;Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea.;Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.;Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.;Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.;Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.;Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.;

关键词: Clinical practice guideline;    Diabetes mellitus, type 2;    Hypoglycemic agents;    Insulin;    Korea;   

DOI  :  10.4093/dmj.2017.41.5.367

来源: DOAJ

【 摘 要 】

The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.

【 授权许可】

Unknown